Mitomycin C-induced hemolytic uremic syndrome: Long-term cure;Syndrome hemolytique et uremique secondaire a la mitomycine C: Guerison a long terme

Annales de Medecine Interne

Volumn 151, Issue 1, 2000, Pages 70-73

  Duvic, Christian ^a   Sarret, Damien ^a   Coutant, Gilles ^a   Herody, Michel ^a   Didelot, Francis ^a   Nedelec, Georges ^a  

^a Hopital d'Instruction   (France)

Author keywords

Chemotherapy; Hemolytic uremic syndrome; Mitomycin C

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; FUROSEMIDE; MITOMYCIN C; NICARDIPINE; PROSTACYCLIN; VINCRISTINE; ANTINEOPLASTIC ANTIBIOTIC; CREATININE; MITOMYCIN; PLASMA SUBSTITUTE;

ADULT; ANTIHYPERTENSIVE THERAPY; ANUS CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG SAFETY; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; LONG TERM CARE; PLASMA TRANSFUSION; PLASMAPHERESIS; PROGNOSIS; THROMBOCYTOPENIA; ANUS TUMOR; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; FOLLOW UP; KIDNEY; LONGITUDINAL STUDY; MIDDLE AGED; PHYSIOLOGY; RECURRENT DISEASE;

ANTIBIOTICS, ANTINEOPLASTIC; ANUS NEOPLASMS; BLOOD PRESSURE; CREATININE; FEMALE; FOLLOW-UP STUDIES; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY; LONGITUDINAL STUDIES; MIDDLE AGED; MITOMYCIN; PLASMA EXCHANGE; PLASMA SUBSTITUTES; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RECURRENCE;

EID: 0034138080     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. REMUZZI G, RUGGENENTI P. The hemolytic uremic syndrome. Kidney Int, 1995; 47: 2-19.
2. GROFF JA, KOZAK M, BOEHMER JP, DEMKO TM, DIAMOND JR. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis, 1997 ; 29: 280-4.
3. CHARBA D, MOAKE JL, HARRIS MA, HESTER JP. Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies. Am J Hematol, 1993; 42: 268-77.
4. GORDON LI, KWAAN HC. Cancer-and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol, 1997; 34: 140-7.
5. WU DC, LIU JM, CHEN YM, et al. Mitomycin-C induced hemolytic syndrome: a case report and literature review. Jpn J Clin Oncol, 1997; 27: 115-8.
6. VERWEY J, DE VRIES J, PINEDO HM. Mitomycin-C induced renal toxicity, a dose-dependent side effect? Eur J Cancer Clin Oncol, 1987; 23: 195-9.
7. HANNA WT, KRAUSS S, REGESTER RF, MURPHY WM. Renal disease after mitomycin C therapy. Cancer, 1981; 48: 2583-8.
8. POCH E, GONZALEZ-CLEMENTE JM, TORRAS A, DARNELL A, BOTEY A, REVERT L. Silent renal microangiopathy after mitomycin C therapy. Am J Nephrol, 1990; 10: 514-7.
9. MOTOO Y, SAWABU N, IKEDA K, et al. Long-term follow-up of mitomycin C nephropathy. Intern Medicine, 1994; 33: 180-4.
10. GARIBOTTO G, ACQUARONE N, SAFFIOTI S, DEFERRARI G, VILLAGIO B, FERRARIO F. Successful treatment of mitomycin C-associated hemolytic uremic syndrome by plasmapheresis. Nephron, 1989; 51: 409-12.
11. HENON PH, pour le GHEM. Traitement du purpura thrombotique thrombopénique. Résultats d'une étude clinique multicentrique randomisée. Presse Med, 1991 ; 20 : 1761-7.
12. D'SOUZA RJ, KWAN JTC, HENDRY BM, FALLON M, CUNNINGHAM D. Successful outcome of treating hemolytic uremic syndrome associated with cancer chemotherapy with immunoadsorption. Clin Nephrol, 1997; 47: 58-9.